Physician profile

Roger A Denney

Anesthesiology · Falls Church, VA

NPI 1013955665

$487.49

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$256.13

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $222.07 2022-2024 Trulance, Xifaxan
Takeda Pharmaceuticals U.S.A., INC. $81.56 2021-2022
Merck Sharp & Dohme LLC $69.40 2023-2024 Bridion
Vertex Pharmaceuticals Incorporated $39.73 2024
Avanos Medical $38.11 2019
Acacia Pharma INC $21.75 2022
Alnylam Pharmaceuticals INC. $14.87 2024 Givlaari

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Roger A Denney

$487.49

in general payments reported 2019-2025

Years
2019-2024
Top company
Salix Pharmaceuticals, A Division of Bausch Health US, LLC

https://glasscript.com/doctor/227850/roger-a-denney

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.